Mavrilimumab + Placebos
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
COVID 19
Conditions
COVID 19, SARS-CoV 2, Pneumonia
Trial Timeline
May 20, 2020 → Apr 23, 2021
NCT ID
NCT04399980About Mavrilimumab + Placebos
Mavrilimumab + Placebos is a phase 2 stage product being developed by Kiniksa Pharmaceuticals for COVID 19. The current trial status is completed. This product is registered under clinical trial identifier NCT04399980. Target conditions include COVID 19, SARS-CoV 2, Pneumonia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04463004 | Phase 2 | Completed |
| NCT04399980 | Phase 2 | Completed |
Competing Products
20 competing products in COVID 19
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Favipiravir + Nitazoxanide | Strides Pharma | Phase 2 | 51 |
| Human COVID-19 immunoglobulin (pH4) for intravenous injection + Placebo | Sinopharm | Phase 2 | 51 |
| mavrilimumab | Kiniksa Pharmaceuticals | Phase 2/3 | 60 |
| Mavrilimumab + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Mavrilimumab + Placebos | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Gimsilumab + Placebo | Roivant Sciences | Phase 2 | 49 |
| Icosapent ethyl | Amarin Corporation | Approved | 77 |
| Icosapent ethyl | Amarin Corporation | Phase 2 | 44 |
| Bamlanivimab + Placebo + Etesevimab | Eli Lilly | Phase 3 | 77 |
| GX-03 + Petrolatum ointment | Turn Therapeutics | Phase 2 | 44 |
| Cytotoxic T Lymphocytes | Tevogen Bio | Phase 1 | 25 |
| Infliximab | Celltrion | Phase 2 | 52 |
| CT-P63 and CT-P66 / Placebo | Celltrion | Phase 3 | 77 |
| DS-5670a + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| Enzalutamide Pill | Astellas Pharma | Phase 2 | 52 |
| S-892216 + Placebo | Shionogi | Phase 2 | 52 |
| S-892216 + Carbamazepine | Shionogi | Phase 1 | 33 |
| Ensitrelvir | Shionogi | Phase 2 | 52 |
| FOY-305 + Placebo | Ono Pharmaceutical | Phase 3 | 77 |
| Desidustat | Zydus Lifesciences | Phase 2 | 52 |